211 related articles for article (PubMed ID: 32271370)
1. Morphologic and Immunocytochemical Features of High-Grade Serous Carcinoma of Ovary in Ascitic Fluid Effusion and Fine-Needle Aspiration Cytology.
Bansal A; Srinivasan R; Rohilla M; Sundaram A; Rai B; Rajwanshi A; Suri V; Saha SC; Gupta N; Gupta P; Dey P
Am J Clin Pathol; 2020 Jun; 154(1):103-114. PubMed ID: 32271370
[TBL] [Abstract][Full Text] [Related]
2. Utility of paired box gene 8 (PAX8) expression in fluid and fine-needle aspiration cytology: an immunohistochemical study of metastatic ovarian serous carcinoma.
McKnight R; Cohen C; Siddiqui MT
Cancer Cytopathol; 2010 Oct; 118(5):298-302. PubMed ID: 20572292
[TBL] [Abstract][Full Text] [Related]
3. Napsin A and WT 1 are useful immunohistochemical markers for differentiating clear cell carcinoma ovary from high-grade serous carcinoma.
Rekhi B; Deodhar KK; Menon S; Maheshwari A; Bajpai J; Ghosh J; Shylasree ST; Gupta S
APMIS; 2018 Jan; 126(1):45-55. PubMed ID: 29266433
[TBL] [Abstract][Full Text] [Related]
4. Value of PAX8 and WT1 Immunostaining in Confirming the Ovarian Origin of Metastatic Carcinoma in Serous Effusion Specimens.
Zhao L; Guo M; Sneige N; Gong Y
Am J Clin Pathol; 2012 Feb; 137(2):304-9. PubMed ID: 22261458
[TBL] [Abstract][Full Text] [Related]
5. [Significance and expression of PAX8, PAX2, p53 and RAS in ovary and fallopian tubes to origin of ovarian high grade serous carcinoma].
Mao YN; Zeng LX; Li YH; Liu YZ; Wu JY; Li L; Wang Q
Zhonghua Fu Chan Ke Za Zhi; 2017 Oct; 52(10):687-696. PubMed ID: 29060967
[No Abstract] [Full Text] [Related]
6. Primary papillary serous carcinoma of the peritoneum: report of a case with diagnosis by fine needle aspiration and immunocytochemistry.
Alberti N; Serrano-Egea A; García-García E; Ballestín C; Pérez-Barrios A; López-Ríos F; de Agustín P
Acta Cytol; 2007; 51(2):203-6. PubMed ID: 17425204
[TBL] [Abstract][Full Text] [Related]
7. A comparison of p53 and WT1 immunohistochemical expression patterns in tubo-ovarian high-grade serous carcinoma before and after neoadjuvant chemotherapy.
Casey L; Köbel M; Ganesan R; Tam S; Prasad R; Böhm S; Lockley M; Jeyarajah AJ; Brockbank E; Faruqi A; Gilks CB; Singh N
Histopathology; 2017 Nov; 71(5):736-742. PubMed ID: 28570008
[TBL] [Abstract][Full Text] [Related]
8. Cytologic changes of ovarian epithelial cancer induced by neoadjuvant chemotherapy.
Wang Y; Wang Y; Zheng W
Int J Clin Exp Pathol; 2013; 6(10):2121-8. PubMed ID: 24133590
[TBL] [Abstract][Full Text] [Related]
9. Gynecologic Serous Carcinoma: An Immunohistochemical Analysis of Malignant Body Fluid Specimens.
Ren S; Klump W
Arch Pathol Lab Med; 2019 Jun; 143(6):677-682. PubMed ID: 29688031
[TBL] [Abstract][Full Text] [Related]
10. A detailed morphological and immunohistochemical comparison of primary endometrial and tubo-ovarian high-grade serous carcinomas and their corresponding omental metastases.
Ruba S; Doherty D; Stewart CJR
Pathology; 2020 Feb; 52(2):197-205. PubMed ID: 31870502
[TBL] [Abstract][Full Text] [Related]
11. Death domain-associated protein (DAXX) expression is associated with poor survival in metastatic high-grade serous carcinoma.
Davidson B; McFadden E; Holth A; Brunetti M; Flørenes VA
Virchows Arch; 2020 Dec; 477(6):857-864. PubMed ID: 32533344
[TBL] [Abstract][Full Text] [Related]
12. PAX8: a sensitive and specific marker to identify cancer cells of ovarian origin for patients prior to neoadjuvant chemotherapy.
Wang Y; Wang Y; Li J; Yuan Z; Yuan B; Zhang T; Cragun JM; Kong B; Zheng W
J Hematol Oncol; 2013 Aug; 6():60. PubMed ID: 23958394
[TBL] [Abstract][Full Text] [Related]
13. [Cytopathological characterization of ascites for the diagnosis of serous ovarian carcinoma].
Chang YH; Zou BQ; Cai Y; Yang SD; Zhang Y; Liang JB; Li C
Zhonghua Zhong Liu Za Zhi; 2023 May; 45(5):424-432. PubMed ID: 37188628
[No Abstract] [Full Text] [Related]
14. Performance of ovarian cyst fluid fine-needle aspiration cytology.
Zhou AG; Levinson KL; Rosenthal DL; VandenBussche CJ
Cancer Cytopathol; 2018 Feb; 126(2):112-121. PubMed ID: 28834408
[TBL] [Abstract][Full Text] [Related]
15. Diagnostic Value of the EZH2 Immunomarker in Malignant Effusion Cytology.
Ang PP; Tan GC; Karim N; Wong YP
Acta Cytol; 2020; 64(3):248-255. PubMed ID: 31352449
[TBL] [Abstract][Full Text] [Related]
16. Primary Peritoneal High-grade Serous Carcinoma Misinterpreted as Metastatic Breast Carcinoma: A Rare Encounter in Peritoneal Fluid Cytology.
Park S; Cho EY; Oh YL; Park YH; Kim HS
Anticancer Res; 2020 May; 40(5):2933-2939. PubMed ID: 32366445
[TBL] [Abstract][Full Text] [Related]
17. Evaluation of cell blocks from effusion specimens in Gynecologic Oncopathology: An experience of 220 cases, diagnosed at a Tertiary Cancer Referral Center.
Rekhi B; Karmarkar S; Gupta C; Deodhar KK; Menon S; Pathuthara S; Maheshwari A; Shylasree TS; Gupta S
Indian J Pathol Microbiol; 2020; 63(3):427-434. PubMed ID: 32769333
[TBL] [Abstract][Full Text] [Related]
18. Combination of MUC5ac and WT-1 immunohistochemistry is useful in distinguishing pancreatic ductal carcinoma from ovarian serous carcinoma in effusion cytology.
Han L; Pansare V; Al-Abbadi M; Husain M; Feng J
Diagn Cytopathol; 2010 May; 38(5):333-6. PubMed ID: 19856421
[TBL] [Abstract][Full Text] [Related]
19. External quality assurance in nongynecologic cytology: The Australasian experience.
Shield PW; Frost F; Finnimore JL; Wright RG; Cummings MC
Cancer Cytopathol; 2017 May; 125(5):349-361. PubMed ID: 28241108
[TBL] [Abstract][Full Text] [Related]
20. Expression of palladin is associated with disease progression in metastatic high-grade serous carcinoma.
Davidson B; Bock AJ; Holth A; Nymoen DA
Cytopathology; 2020 Nov; 31(6):572-578. PubMed ID: 32741023
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
